PRKN and Parkinson disease: Third, we prioritized pdRGs by aggregated gene regulatory features from the xQTL evidence [16] and validated those pdRGs using multi-omics approaches, including transcriptome dysregulation from single-nuclei RNA sequencing (snRNA-seq) data from human brains with PD, parkin-dependent substrates, alpha-synuclein (α-syn) modifiers, gene expression in human brain substantia nigra (SN) region, and pathway enrichment analysis (cf. Methods).